Finney Joseph Daniel, Schuler Paul D, Rudloff James R, Agostin Nicholas, Lobanov Oleg V, Siegler Jeffrey, Shah Manish I, Guterman Elan L, Chamberlain James M, Ahmad Fahd A
Department of Pediatrics, Washington University in Saint Louis, Saint Louis, Missouri.
Department of Emergency Medicine, School of Medicine, University of Missouri, Columbia, Missouri.
Prehosp Emerg Care. 2025;29(5):624-631. doi: 10.1080/10903127.2024.2382367. Epub 2024 Jul 31.
Benzodiazepines are the primary antiseizure medication used by Emergency Medical Services (EMS) for seizures. Available literature in the United States and internationally shows 30% to 40% of seizures do not terminate with benzodiazepines called benzodiazepine refractory status epilepticus (BRSE). Ketamine is a potential treatment for BRSE due to its unique pharmacology. However, its application in the prehospital setting is mostly documented in case reports. Little is known about its use by EMS professionals for seizure management, whether as initial treatment or for BRSE, creating an opportunity to describe its current use and inform future research.
We performed a retrospective review of 9-1-1 EMS encounters with a primary or secondary impression of seizure using the ESO Data Collaborative from 2018 to 2021. We isolated encounters during which ketamine was administered. We excluded medication administrations prior to EMS arrival and encounters without medication administration. Subgroup analysis was performed to control for airway procedure as an indication for ketamine administration. We also evaluated for co-administration with other antiseizure medications, dose and route of administration, and response to treatment.
We identified 99,576 encounters that met inclusion. There were 2,531/99,576 (2.54%) encounters with ketamine administration and 50.7% (1,283/2,531) received ketamine without an airway procedure. There were 616 cases (48%, 616/1,283) where ketamine was given without another antiseizure medication (ASM) and without any airway procedure. The remaining 667 (52%) cases received ketamine with at least one other ASM, most commonly midazolam (89%, 593/667). Adjusted for the growth in the ESO dataset, ketamine use by EMS professionals during encounters for seizures without an airway procedure increased from 0.90% (139/15,375) to 1.45% (416/28,651) an increase of 62% over the study period.
In this retrospective review of the ESO Data Collaborative, ketamine administration for seizure encounters without an airway procedure increased over the study period, both as a single agent and with another ASM. Most ketamine administrations were for adult patients in the south and in urban areas. The frequency of BRSE, the need for effective treatment, and the growth in ketamine use warrant prospective prehospital research to evaluate the value of ketamine in prehospital seizure management.
苯二氮䓬类药物是紧急医疗服务(EMS)用于治疗癫痫发作的主要抗癫痫药物。美国和国际上的现有文献表明,30%至40%的癫痫发作不能通过苯二氮䓬类药物终止,即所谓的苯二氮䓬难治性癫痫持续状态(BRSE)。氯胺酮因其独特的药理学特性,是治疗BRSE的一种潜在药物。然而,其在院前环境中的应用大多记录在病例报告中。对于EMS专业人员将其用于癫痫管理,无论是作为初始治疗还是用于BRSE,人们知之甚少,这为描述其当前使用情况并为未来研究提供信息创造了机会。
我们使用ESO数据协作平台对2018年至2021年期间9-1-1 EMS遇到的以癫痫发作作为主要或次要印象的情况进行了回顾性研究。我们分离出了使用氯胺酮的情况。我们排除了EMS到达之前的药物给药情况以及未进行药物给药的情况。进行亚组分析以控制气道操作作为使用氯胺酮的指征。我们还评估了与其他抗癫痫药物的联合使用、给药剂量和途径以及治疗反应。
我们确定了99576次符合纳入标准的情况。有(253篇/99576篇,2.54%)使用氯胺酮的情况,其中50.7%(1283篇/2531篇)在没有气道操作的情况下使用了氯胺酮。有616例(48%,616篇/1283篇)在没有使用其他抗癫痫药物(ASM)且没有任何气道操作的情况下使用了氯胺酮。其余667例(52%)在使用氯胺酮时至少联合使用了一种其他ASM,最常见的是咪达唑仑(89%,593篇/667篇)。根据ESO数据集的增长情况进行调整后,EMS专业人员在没有气道操作的癫痫发作情况中使用氯胺酮的比例从0.90%(139篇/15375篇)增加到1.45%(416篇/28651篇),在研究期间增加了62%。
在对ESO数据协作平台的这项回顾性研究中,在没有气道操作的癫痫发作情况下使用氯胺酮的情况在研究期间有所增加,无论是作为单一药物还是与其他ASM联合使用。大多数氯胺酮的使用是针对南部和城市地区的成年患者。BRSE的发生率、有效治疗的需求以及氯胺酮使用的增加,都需要进行前瞻性的院前研究,以评估氯胺酮在院前癫痫管理中的价值。